pegaptanib: Clinical Trials

11 trials of pegaptanib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 3 terminated, 3 unknown. 11 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 411Completed 5, Terminated 3, Unknown 3

Follow pegaptanib: new trials by email Literature Review of pegaptanib trials Research Report on pegaptanib

Trials (filtered) newest first · largest first

All 11 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Cohort Study of the Clinical Course of Macular Diseases in Kagawa
ranibizumab, aflibercept, pegaptanib, verteporphin - Macular Disease
Phase 4UnknownKagawa University10002014-12-012018-03-07
Intravitreal Macugen for Ischaemic Diabetic Macular Oedema
Intravitreal injection of pegaptanib sodium - Diabetic Macular Oedema
Phase 4CompletedUniversity of Oxford302011-01-012014-12-24
Extension Study to Gather Data on Effect of Macugen on the Corneal Endothelium
pegaptanib sodium injection - Age-Related Macular Degeneration, Retinal Vein Occlusion
Phase 4CompletedBausch & Lomb Incorporated1312010-04-222021-01-08
Pegaptanib for Retinal Edema Secondary to Diabetic Vascular Disease(Preserve) Study
Macugen® pegaptanib sodium - Diabetic Macular Edema
Phase 4CompletedValley Retina Institute722009-04-012013-07-16
Macugen for Proliferative Diabetic Retinopathy Study With Extended Dosing (M-PDRS ED)
Macugen ® (pegaptanib sodium) - Proliferative Diabetic Retinopathy
Phase 4UnknownValley Retina Institute302007-11-012011-12-06
An Open Label Trial to Investigate Macugen for the Preservation of Visual Function in Subjects With Neovascular AMD
Pegaptanib Sodium 0.3 mg - Age Related Macular Degeneration (AMD), Macular Degeneration
Phase 4TerminatedPfizer2882006-07-012012-04-04
Evaluation Of Safety And Efficacy Of 0.3 Mg/Eye Macugen In Patients With Small Age-Related Macular Degeneration Lesions
pegaptanib sodium (Macugen) - Macular Degeneration
Phase 4CompletedPfizer812006-07-012010-03-23
A Clinical Trial to Explore the Safety and Efficacy of Injections of Macugen When Given Every 6 Weeks in Subjects With AMD
pegaptanib sodium (Macugen) - Age-Related Macular Degeneration (AMD)
Phase 4UnknownEyetech Pharmaceuticals10002006-06-012007-01-15
A Clinical Trial to Explore the Safety and Efficacy of Three Different Doses of Pegaptanib Sodium in Patients With Wet Age-Related Macular Degeneration (AMD)
Pegaptanib sodium - Macular Degeneration
Phase 4TerminatedEyetech Pharmaceuticals2622006-04-012007-01-15
Evaluation of Macugen Treatment of Macular Edema Due to Branch Retinal Vein Occlusion
pegaptanib sodium (Macugen) - Branch Retinal Vein Occlusion
Phase 4CompletedPalmetto Retina Center, LLC202006-01-012014-09-12
Macugen (Pegaptanib Sodium) Alone, Versus Macugen in Combination With PDT (Photodynamic Therapy) With Visudyne (Verteporfin) in Patients With Age-Related Macular Degeneration (AMD)
Photodynamic Therapy (PDT) with Visudyne (verteporfin), Macugen (pegaptanib sodium) - Age-Related Macular Degeneration
Phase 4TerminatedEyetech Pharmaceuticals3602005-03-012007-01-15

Conditions studied

Macular Degeneration (7)  ·  Retinal Vein Occlusion (2)  ·  Choroidal Neovascularization (1)  ·  Ischemia (1)  ·  Macular Edema (1)

Sponsors

Eyetech Pharmaceuticals (3)  ·  Pfizer (2)  ·  Valley Retina Institute (2)  ·  Bausch & Lomb Incorporated (1)  ·  Kagawa University (1)  ·  Palmetto Retina Center, LLC (1)  ·  University of Oxford (1)

Countries

United States (7)  ·  France (2)  ·  United Kingdom (2)  ·  Austria (1)  ·  Belgium (1)  ·  Canada (1)  ·  Czechia (1)  ·  Denmark (1)  ·  Finland (1)  ·  Germany (1)  ·  Greece (1)  ·  Italy (1)  ·  Japan (1)  ·  Poland (1)  ·  Portugal (1)

Top investigators

Akiataka Tsujikawa, MD (1)  ·  John A Wells, III, MD (1)  ·  Mandeep Kaur, M.D. (1)  ·  Victor Chong, MPhil, MD, FRCSEd, FRCOphth (1)  ·  Victor Gonzalez, Dr. (1)  ·  Victor H. Gonzalez, MD (1)

Results publications

PMID 20472746, PMID 22872673